Skip to main content

Table 1 Maternal and infant safety outcomes of artemether and lumefantrine use during pregnancy

From: A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy

Publication Drug (n) Trimester Maternal outcomes Infant outcomes
1 2/3 AE SAE Death Normal development Death, 1 yr
Wang 1989[20] A 0 2     2/2a  
Sowunmi et al., 1998[15] A + MQ (22), A (23) 0 45 Minimal    Yesb  
McGready et al. , 2001[17] A + MQ/AS/C (10), AL (1)   0/9c 1/9d   
Adam et al., 2004[16] A 1 27    0/28   
McGready et al., 2006[21] AL 0 13*   0/13   9/10e  
McGready et al. , 2008[22] AL 0 125   1c,f 1g   1/117 (0.9%)h
AS 0 128   0c 0   8/120 (6.7%)i
Kaye et al. , 2008[23] AL 0 58 7     
Adam et al., 2009[24] A (48), AL (3) 51 0    0   0/49
Piola et al. , 2010[25] AL 0 152 94/152 (61.8%)j   0   
Q 0 152 142/152 (93%)j   1k   
Manyando et al. , 2010[26] ALl 156 348   108/495 (21.8%) 1 (0.2%)m   
SP/Ql 138 378   SP 118/506 (23.3%) 5 (1%)n   
Sangaré et al., 2011[27] AL (260)o 53p 207      
  1. A artemether; AE adverse events; AL artemether-lumefantrine; AS artesunate; C clindamycin; IM intramuscular; MQ mefloquine; Q quinine; SAE serious adverse event; SP sulphadoxine-pyrimethamine; *These 13 exposures are not included in the total count of exposures to AL in pregnant women as they were also included in McGready, et al. 2008 [22]; a5 years; bphysical and neurodevelopment within normal limits (6–36 months); cdrug related; dsevere malaria and anaemia; e1 year; fDay 2 increase in parasitaemia; ghaemorrhagic shock (treatment not suspected); hsuspected intraventricular haemorrhage, background of Allagile’s syndrome; i3 related to prematurity, 2 pneumonia, 1 sepsis, 1 diarrhoea, 1 suspected beriberi; jnumber reporting at least 1 AE; ksepsis following a caesarean section; lAL group n = 495, AL exposure n = 504, SP group n = 506, SP/Q exposure n = 516; manaemia secondary to spontaneous abortion; n1 related to Kaposi’s sarcoma, 3 infections, 1 undiagnosed illness; o260 reports of AL treatment for an episode of malaria; p26 received only AL in the 1st trimester.
\